(R)-N-((S)-5-(2-Fluoroethylamino)-1-hydroxy-5-oxopentan-2-yl)-N,9-dimethyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-1H-carbazole-6-carboxamide | 1121526-50-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: (R)-N-((S)-5-(2-Fluoroethylamino)-1-hydroxy-5-oxopentan-2-yl)-N,9-dimethyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-1H-carbazole-6-carboxamide
• 英文别名: (6R)-N-[(2S)-5-(2-fluoroethylamino)-1-hydroxy-5-oxopentan-2-yl]-N,9-dimethyl-6-(oxan-4-yl)-5,6,7,8-tetrahydrocarbazole-3-carboxamide
• CAS: 1121526-50-8
• 化学式: C₂₇H₃₈FN₃O₄
• 分子量: 487.615
• InChiKey: LHROVEQUEJTMFN-CTNGQTDRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  35
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.63
• 拓扑面积：
  83.8
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  methyl 3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-1H-carbazole-6-carboxylate 在 水 、 sodium hydride 、 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 、 lithium hydroxide 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 乙醇 、 正己烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 (R)-N-((S)-5-(2-Fluoroethylamino)-1-hydroxy-5-oxopentan-2-yl)-N,9-dimethyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-1H-carbazole-6-carboxamide
  参考文献：
  名称：

  N-Methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-1H-carbazole-6-carboxamides as a novel class of cannabinoid receptors agonists with low CNS penetration

  摘要：

  Cannabinoid CB1 receptor agonists exhibit potent analgesic effects in rodents and humans, but their clinical utility as analgesic drugs is often limited by centrally mediated side effects. We report herein the preparation of N-methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-1H-carbazole-6-carboxamides as a novel class of hCB(1)/hCB(2) dual agonists with attractive physicochemical properties. More specifically, (R)-N,9-dimethyl-N-(4-(methylamino)-4-oxobutyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-1H-carbazole-6-carboxamide, displayed an extremely low level of CNS penetration (Rat Cbr/Cplasma = 0.005 or 0.5%) and was devoid of CNS side effects during pharmaco-dynamic testing. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.04.128

文献信息

• Novel Compounds 002
  申请人：Beha Sara

  公开号：US20090062251A1

  公开（公告）日：2009-03-05

  Compounds of Formulae I, or pharmaceutically acceptable salts thereof: wherein R 1 , R 2 and Y are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.

  式I的化合物，或其药用可接受的盐： 其中R1、R2和Y如规范中定义的那样，以及包括这些化合物的盐和药物组合物已经准备好。它们在治疗中很有用，特别是在疼痛管理中。
• Cannabinoid Receptor Ligands
  申请人：Beha Sara

  公开号：US20110160180A1

  公开（公告）日：2011-06-30

  Compounds of Formulae (I), or pharmaceutically acceptable salts thereof: wherein R 1 , R 2 and Y are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.

  化学式（I）的化合物，或其药学上可接受的盐：其中R1，R2和Y的定义如规范中所述，以及包括这些化合物的盐和药物组合物已经制备。它们在治疗中有用，特别是在疼痛管理中。
• CANNABINOID RECEPTOR LIGANDS
  申请人：AstraZeneca AB

  公开号：EP2190838A1

  公开（公告）日：2010-06-02
• [EN] CANNABINOID RECEPTOR LIGANDS<br/>[FR] LIGANDS DES RÉCEPTEURS CANNABINOÏDES
  申请人：ASTRAZENECA AB

  公开号：WO2009024819A1

  公开（公告）日：2009-02-26

  Compounds of Formulae (I), or pharmaceutically acceptable salts thereof: wherein R1, R2 and Y are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.